New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices : Episode 16
Opinion
Video
Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL
Author(s):
A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.
EP: 1.Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning
EP: 2.Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
EP: 3.Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies
EP: 4.Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population
EP: 5.Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study
EP: 6.Panel Discuses Use of CD19 Bispecifics in Sequencing
EP: 7.Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion
EP: 8.Current Approach to Bridging Therapy in R/R DLBCL
EP: 9.Risk of Secondary Malignancies in Heavily Pre-Treated Population
EP: 10.Management of CRS and ICANS with CAR T-cell Therapy
EP: 11.Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line
EP: 12.Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy
EP: 13.Bispecific therapy – treatment setting and management of short-term adverse events
EP: 14.Bispecific therapy – management of long-term adverse events in the community setting
EP: 15.Practice Patterns and Real Use of Epcoritamab and Glofitamab
Now Viewing
EP: 16.Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL
Video content above is prompted by the following:
- What are your thoughts on the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL, specifically related to sequencing and transplant eligibility?
Related Videos
Related Content
